株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

原発性胆汁性肝硬変(PBC) : パイプライン分析

Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 200481
出版日 ページ情報 英文 150 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
原発性胆汁性肝硬変(PBC) : パイプライン分析 Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline Review, H2 2019
出版日: 2019年08月30日 ページ情報: 英文 150 Pages
概要

原発性胆汁性肝硬変(PCB)は肝臓の慢性疾患で、自己免疫性があるとされ、進行性の胆汁うっ帯や、時には末期肝疾患にまで進行することがあります。PBCの患者は女性がほとんどで、また50~60歳代で発症するケースが最も多くなっています。

当レポートでは、世界各国での原発性胆汁性肝硬変(以下PBC)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 分析範囲

原発性胆汁性肝硬変(PBC)の概要

治療薬の開発

  • PBC向けパイプライン製品:概要
  • PBC向けパイプライン製品:比較分析

各企業で開発中のPBC治療薬

大学/研究機関で研究中のPBC治療薬

パイプライン製品の概略

  • 最終段階の製品
  • 治験段階の製品
  • 初期段階の製品

PBC治療薬:開発中の製品の一覧(企業別)

PBC治療薬の開発に従事している企業

  • AlbireoPharma
  • CymaBay Therapeutics, Inc.
  • Dr. Falk Pharma GmbH
  • Enanta Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Intercept Pharmaceuticals, Inc.
  • Johnson & Johnson
  • MediGene AG
  • NGM Biopharmaceuticals, Inc.
  • Virobay Inc.

原発性胆汁性肝硬変(PBC):治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • A-4250
  • budesonide
  • FFP-104
  • GSK-2330672
  • MBX-8025
  • NGM-282
  • obeticholic acid
  • RhuDex
  • Small Molecules to Agonize Farnesoid X Receptor for Non-alcoholic Steatohepatitis and Primary Biliary Cirrhosis
  • ustekinumab
  • VBY-825

PBC治療薬:最新の薬剤プロファイル

PBC関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Albireo Pharma Inc, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Allergan Plc, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Biocad, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Cadila Healthcare Ltd, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Calliditas Therapeutics AB, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by CymaBay Therapeutics Inc, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Dr. Falk Pharma GmbH, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Eli Lilly and Co, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Enanta Pharmaceuticals Inc, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Genfit SA, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by GenKyoTex SA, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Gilead Sciences Inc, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Kowa Co Ltd, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by NGM Biopharmaceuticals Inc, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Novartis AG, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Tiziana Life Sciences Plc, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Pipeline by Virobay Inc, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects, H2 2019
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11371IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cholangitis - Pipeline Review, H2 2019, provides an overview of the Primary Biliary Cholangitis (Gastrointestinal) pipeline landscape.

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cholangitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Primary Biliary Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 2, 11, 3, 1, 1 and 3 respectively.

Primary Biliary Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cholangitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Primary Biliary Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Biliary Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Biliary Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cholangitis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cholangitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Biliary Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Overview
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Companies Involved in Therapeutics Development
    • Albireo Pharma Inc
    • Allergan Plc
    • Biocad
    • Cadila Healthcare Ltd
    • Calliditas Therapeutics AB
    • CymaBay Therapeutics Inc
    • Dr. Falk Pharma GmbH
    • Eli Lilly and Co
    • Enanta Pharmaceuticals Inc
    • Genfit SA
    • GenKyoTex SA
    • Gilead Sciences Inc
    • Kowa Co Ltd
    • NGM Biopharmaceuticals Inc
    • Novartis AG
    • Suzhou Zelgen Biopharmaceutical Co Ltd
    • Tiziana Life Sciences Plc
    • Virobay Inc
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Drug Profiles
    • ABC-08 - Drug Profile
    • baricitinib - Drug Profile
    • bezafibrate SR - Drug Profile
    • budesonide - Drug Profile
    • Cilofexor - Drug Profile
    • EDP-305 - Drug Profile
    • elafibranor - Drug Profile
    • foralumab - Drug Profile
    • netakimab - Drug Profile
    • NGM-282 - Drug Profile
    • odevixibat - Drug Profile
    • pemafibrate - Drug Profile
    • PRI-724 - Drug Profile
    • saroglitazar - Drug Profile
    • seladelpar lysine - Drug Profile
    • setanaxib - Drug Profile
    • TQA-3526 - Drug Profile
    • tropifexor - Drug Profile
    • ursodiol - Drug Profile
    • VBY-825 - Drug Profile
    • ZG-5266 - Drug Profile
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Dormant Projects
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Discontinued Products
  • Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top